In a patient with chronic hypertension and dyslipidemia, what is the next action if their blood pressure measurement shows 150/88 mm Hg?

In a patient with chronic hypertension and dyslipidemia, the next action upon finding a blood pressure measurement of 150/88 mm Hg aligns with the initiation of pharmacotherapy to achieve better blood pressure control. Starting an ACE inhibitor in this scenario is particularly appropriate for several reasons.

First, the blood pressure reading indicates stage 1 hypertension; guidelines suggest initiating treatment in individuals with a high cardiovascular risk or those with comorbidities, such as dyslipidemia. ACE inhibitors are known to provide cardiovascular protective benefits beyond blood pressure control, particularly beneficial for patients with concurrent dyslipidemia and an increased cardiovascular risk profile.

Additionally, ACE inhibitors assist in renal protection, especially relevant in patients with diabetes or chronic kidney disease, which can often coexist with hypertension and dyslipidemia. Starting this medication early can effectively reduce blood pressure over time and aid in managing overall cardiovascular risk.

Education on lifestyle changes is important but is typically more of an adjunct to pharmacotherapy rather than the only intervention. While beta-blockers can be considered in certain clinical scenarios, they are not generally the first line for uncomplicated hypertension in the absence of other specific indications such as ischemic heart disease or heart failure. Simply advising to recheck blood pressure in one month without initiating treatment